At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 36 enrolled
Drug / intervention
0.9 % sodium chloride +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
COR-1, an Anti-Beta1 Receptor Antibody Cyclopeptide in Heart Failure: a Phase II, Multicentre, Randomised, Double-Blind and Placebo-Controlled Study With Parallel Groups
In Brief
A Phase 2 clinical trial evaluating 0.9 % sodium chloride, COR-1, and 1 other intervention for Cardiomyopathy, Dilated. Completed, enrolled 36 participants across 4 sites.
Detailed Summary
The purpose of this study is to investigate the effect of COR-1 in combination with standard therapy in patients with heart failure. The safety and tolerability of COR-1 will also be assessed.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiomyopathy, Dilated
CountriesGermany
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 2011
Enrollment StartOct 2011
Primary CompletionAug 2013
TodayJul 2026
First PostedJul 12, 2011
Enrollment StartOct 1, 2011
Primary CompletionAug 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 15.0 years ago
Interventions
0.9 % sodium chloridedrug
Monthly intravenous injection for 6 months
COR-1drug
Monthly intravenous injection for 6 months
Standard therapy for heart failuredrug
All patients will continue to receive standard therapy for heart failure (ie, in accordance with guidelines) throughout the study.